Screener
Capricor Therapeutics CAPR Business Segments — Income Tax Expense Benefit
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Capricor Therapeutics’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-029580
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 |
|---|---|---|
| Operating loss | (108,142,130) | (42,563,242) |
| Investment income | 6,257,607 | 2,202,990 |
| Interest expense | (3,045,725) | — |
| Other income (expense) | (112,098) | (105,334) |
| Total non-operating income, net | 3,099,784 | 2,097,656 |
| Loss before income taxes | (105,042,346) | (40,465,586) |
| (Provision for) benefit from income taxes | (1,600) | (1,600) |
| Net loss | $(105,043,946) | $(40,467,186) |
ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Capricor Therapeutics's business segments — income tax expense benefit?
- Capricor Therapeutics (CAPR) reported business segments — income tax expense benefit of $400 in Q4 2025.
- How has Capricor Therapeutics's business segments — income tax expense benefit changed year-over-year?
- Capricor Therapeutics's business segments — income tax expense benefit decreased by 0.0% year-over-year, from $400 to $400.
- What does business segments — income tax expense benefit mean?
- This represents the amount of income tax expense accrued or the benefit recognized by the company based on its taxable earnings or losses. For companies with significant operating losses, this often reflects minimal tax liability or potential deferred tax assets. It is a necessary component for calculating the final net income of the business.
Ask your AI about Capricor Therapeutics's business segments — income tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude